MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress. “Many of the drugs we use lose efficacy over time, but we now have 2-year data of deucravacitinib, and it is a completely flat line. Patients who did well continue to do just as well 2
MILAN — Patients with atopic dermatitis of the head and neck who did not have success with topical therapy experienced greater improvement with rocatinlimab treatment.
“For all of our patients with atopic dermatitis, the head and neck are an area of big concern to them. The face is our business card, and it’s important we don’t have rashes on the face,” Emma
MILAN — Higher doses of povorcitinib were more efficacious in the treatment of hidradenitis suppurativa compared with lower doses, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“This is a really fun study because it’s starting to look at the [Janus kinase (JAK)] inhibitors and especially the selective JAK inhibitors,”
MILAN — Pediatric patients experienced improved psoriasis symptoms and quality of life with ixekizumab treatment, according to a poster presented at the European Academy of Dermatology and Venereology Congress.
“About 1% of children and adolescents worldwide are affected by plaque psoriasis (PsO),” Andreas Pinter, MD, medical director of clinical research and senior physician in
The FDA has approved Zoryve cream for the treatment of plaque psoriasis, Arcutis announced in a press release.
A nonsteroid, phosphodiesterase-4 inhibitor, Zoryve (roflumilast cream 0.3%) is a once-daily topical treatment for psoriasis and the first PDE4 inhibitor approved for this indication.